secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001193125-22-256710
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences enters $150M ATM equity offering facility with Virtu Americas
------------------------------------------------------------------------------

- Company may sell up to $150M of common stock at prevailing market prices through Agent Virtu Americas LLC.
- Agent receives commission up to 3.0% of gross proceeds; no obligation for Company to sell any shares.
- Shares issued under shelf registration statement filed with SEC on October 3, 2022.
- Either party may terminate the Sales Agreement at any time on prior written notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312522256710/0001193125-22-256710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312522256710/d378227d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-256710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer